Kadimastem To Initiate a Human Clinical Trial for Promising ALS Therapy

This week, Kadimastem, an innovative Israeli biotechnology company focused on the industrial development and commercialization of human pluripotent stem cell (hPSC)-based therapeutic solutions for the neurodegenerative diseases Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS), announced that it plans to begin human trials using its stem-cell technology to…

A study published in the latest edition of Nature Immunology presents evidence that a key protein associated with Amyotrophic lateral sclerosis (ALS) also plays an important role in a patient’s immune response to viral infections.  The study entitled, “Senataxin suppresses the antiviral transcriptional…

In a recent study titled “Senataxin suppresses the antiviral transcriptional response and controls viral biogenesis,” published in the journal Nature Immunology, researchers at Mount Sinai Hospital/Mount Sinai School of Medicine found that a human protein called senataxin (SETX), which has been found to…

Changes in a house-keeping gene that cleans up damaged proteins from cells may be in part to blame for Lou Gehrig’s disease, according to a study published online March 24 in Nature Neuroscience, titled “Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia.” Lou Gehrig’s…

Researchers at the Second University of Naples and the University of Parma in Italy recently characterized the microstructural brain alterations in patients with amyotrophic lateral sclerosis (ALS) during disease progression. The findings were published in the journal PLoS ONE and the study is entitled…

Pharmaceutical company AB Science SA received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy for amyotrophic lateral sclerosis (ALS), called masitinib. The drug is a protein kinase inhibitor (PKI) and was granted the status in order to accelerate its…

A recent study from Sweden’s KTH Royal Institute of Technology (KTH) revealed three proteins that are associated with the progress of amyotrophic lateral sclerosis (ALS). The research team from the KTH and Science for Life Laboratory led by Anna Häggmark believe that the research is the most comprehensive plasma…

Massachusetts-based pharmaceutical company Biogen Idec Inc. has decided to rebrand the company with a shorter name and a new logo, as well as by refocusing its work and abandoning its near exclusivity to multiple sclerosis (MS) drugs to also include research on conditions such as amyotrophic lateral sclerosis (ALS).

A research team at Penn Medicine recently found that hypermethylation is able to inhibit the development of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) in a study titled, “C9orf72 promoter hypermethylation is neuroprotective: Neuroimaging and neuropathologic evidence.” The results are published in the journal…

Researchers at Johns Hopkins University recently published in the journal PLOS ONE a novel resource to aid in studies focused on amyotrophic lateral sclerosis (ALS) pathogenesis and related drug development. The study is entitled “A Comprehensive Library of Familial Human Amyotrophic Lateral Sclerosis…